Navigation Links
ThromboGenics NV Announces Business Update and Half Year Results 2009
Date:8/27/2009

In January 2009, ThromboGenics started the Phase III clinical program of microplasmin for the non-surgical treatment of back of the eye disease. Patient recruitment in this Phase III program is going well and a review by the independent Data Monitoring Committee (DMC) in June led to no changes in the protocols of the two pivotal trials. ThromboGenics expects to be able to report results of these studies from mid of 2010 onwards.

The microplasmin Phase III program comprises two clinical trials, one taking place in the United States (TG-MV-006 trial) and a second combined European/US study (TG-MV-007 trial). The indication for both of these Phase III microplasmin trials is the non-surgical treatment of focal vitreomacular adhesion. Vitreomacular adhesion is a condition in which the vitreous has an abnormally strong adhesion to the retina at the back of the eye. These adhesions can cause vessel and retinal distortion which results in deterioration in the patient's vision. Both of these trials, which will each recruit 320 patients, are using 125ÿ¼g of microplasmin.

Given the good progress that is being made with the Phase III program, ThromboGenics is now starting the initial activities needed to ensure the successful commercialization of this exciting product. Market research is being initiated to provide a clear understanding of how patients with back of the eye diseases are treated. This will provide the detailed market knowledge needed to commercialize the product.

It is ThromboGenics' intention that, if successful, the Company would take this unique product further using its own resources. This is due to the very promising data that the Company has generated to date, the limited competition, and the large potential market for microplasmin with a focused prescribing group. Preliminary market research conducted by the Company suggests that this can be addressed by the small focused commercial
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ThromboGenics NV: Business Update
2. ThromboGenics Announces Business Update and 2008 Full Year Results
3. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
4. ThromboGenics N.V.: Business Update
5. ThromboGenics Announces Half Year Results 2008
6. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
7. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
8. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
9. ThromboGenics N.V. - Business Update
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. ThromboGenics Announces 2007 Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... ... most successful food and beverage processors, equipment manufacturers and leaders in the field ... and industrial weighing and formulation for manufacturers of bakery and snacks; beverages; dairy; ...
(Date:8/30/2015)... England , August 31, 2015 ...   einer Frau   für chirurgische   Behandlung     ... von 7-90   werden für eine   verheerende ... 1200 Frauen behandeln und die Anzahl ausgebildeter Chirurgen in ... Astellas gab heute bekannt, dass  Action on Fistula ...
(Date:8/28/2015)... ... 2015 , ... Proove Biosciences , a commercial and ... Intervention Society’ s 23rd Annual Scientific Meeting (ASM). The ASM event took ... on evidence-based research and clinical application, the event gathered industry thought leaders to ...
(Date:8/28/2015)... ... 28, 2015 , ... Riordan-McKenna Institute founders, stem ... that the use of sterile, dehydrated amniotic tissue AlphaPATCH™ developed by Amniotic ... surgical knee wound. , The case involved a 78-year-old male, who presented with ...
Breaking Biology Technology:METTLER TOLEDO Hosts Food Safety Educational Center at 2015 PROCESS EXPO 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4
... Researchers from A*STAR Singapore took lead roles in a ... during long-term culture of human embryonic stem cells (hESCs). ... Peter Andrews of the University of Sheffield (UK), Paul ... Oh of Singapore,s Bioprocessing Technology Institute (BTI), and Barbara ...
... November 28, 2011 Elsevier ... analytic solutions, today announced that Thomas H. Zajac ... / MEDai provides solutions for providers, health plans ... profiling, regulatory compliance and clinical surveillance to improve ...
... Pelleve™ Wrinkle Reduction System was featured in a live ... Top dermatologist Dr. Ava Shamban of Santa Monica, CA ... first-hand look at how Pelleve works. The treatment produced ... takes to watch the show. A revolutionary, ...
Cached Biology Technology:Singapore scientists lead human embryonic stem cell study 2Singapore scientists lead human embryonic stem cell study 3Elsevier / MEDai Appoints Tom Zajac as New President 2Elsevier / MEDai Appoints Tom Zajac as New President 3Ellman's Pelleve™ Wrinkle Reduction System featured in "Sexy Eyes" segment on The Doctors 2
(Date:8/3/2015)... Synaptics, Inc. (Nasdaq: SYNA ), the ... members of the executive management team will present to ... Leadership Forum on Tuesday, August 11, 2015 at 1:00 ... the Sonnenalp Resort in Vail, CO. ... information. An audio webcast of the event will be ...
(Date:7/31/2015)... , 31 de julio de 2015 BGI llevará ... www.icg-10.org ) del 22 al 25 de octubre de ... La conferencia celebra su décimo aniversario este año. ... en una de las reuniones anuales más influyentes del ... una de las conferencias científicas más dinámicas, entusiastas y ...
(Date:7/31/2015)... , Chine, 31 juillet 2015 ... www.icg-10.org ) sera organisée par le BGI ... Shenzhen en Chine. ... Depuis son inauguration en 2006, l,ICG est devenue ... dans le domaine des « omiques » et c,est aussi ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... part of the Genome Canada Large-Scale Applied Research Project ... to 16 projects across the country, the researchers in ... with the aim of identifying genes or proteins for ... target cancers and other diseases. The first project, ...
... - New research from the University of Calgary,s Faculty ... diagnosis using an iPhone application with the same accuracy ... technology can be particularly useful in rural medical settings. ... neurologists, regardless of where the physicians and patients are ...
... has revealed how infection by a parasitic fungus dramatically changes ... leonardi ), causing them to become zombie-like and to die ... fungus. The multinational research team studied ants living high up ... research will be published in the BioMed Central open-access journal ...
Cached Biology News:OGI genomics researchers awarded $23 million 2OGI genomics researchers awarded $23 million 3iPhone can diagnose stroke: study 2Zombie ants have fungus on the brain, new research reveals 2
...
Yields DNA greater than 50 kb in length from yeast, fungi, Gram neg. and Gram pos. bacteria...
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
B3GALT2 Immunogen: B3GALT2 (NP_003774, 324 a.a. ~ 423 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: